경피 약물전달 시스템 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Transdermal Drug Delivery Systems Market size is expected to reach USD 219.59 Billion in 2034 from USD 78.68 Billion (2025) growing at a CAGR of 12.08% during 2026-2034.

The global transdermal drug delivery systems market is experiencing strong growth due to increasing demand for non-invasive and controlled drug administration methods. These systems deliver drugs through the skin, offering advantages such as improved patient compliance, reduced side effects, and sustained release of medication. They are widely used for pain management, hormone therapy, and chronic disease treatment.

Key drivers include rising prevalence of chronic diseases, advancements in drug delivery technologies, and increasing preference for convenient treatment options. Pharmaceutical companies are investing in innovative patch designs and formulations to enhance drug absorption and effectiveness. Additionally, the aging population is contributing to increased demand for easy-to-use medical solutions.

In the future, the market is expected to benefit from the development of smart patches and integration with wearable technologies. These advancements will enable real-time monitoring and personalized treatment. As healthcare continues to prioritize patient-centric solutions, the transdermal drug delivery systems market is set for sustained global growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Electroporation
• Radio Frequency
• Iontophoresis
• Microporation
• Thermal
• Mechanical Arrays
• Ultrasound
• Others

By Application

• CNS
• Pain Management
• Cardiovascular
• Hormone
• Immunological
• Metabolic
• Gastrointestinal
• Infection
• Cancer
• Others

COMPANIES PROFILED

• Novartis AG, Johnson Johnson, Mylan Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Grnenthal GmbH, AbbVie Inc, 3M Company, Noven Pharmaceuticals Inc, 4P Therapeutics LLC, Hisamitsu Pharmaceutical Co Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Electroporation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Radio Frequency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Iontophoresis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Microporation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thermal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Mechanical Arrays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Ultrasound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Hormone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Immunological Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Metabolic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Technology
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Technology
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Technology
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Technology
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Technology
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Novartis AG
  • 8.2.2 Johnson & Johnson
  • 8.2.3 Mylan Pharmaceuticals Inc
  • 8.2.4 Boehringer Ingelheim GmbH
  • 8.2.5 Grunenthal GmbH
  • 8.2.6 AbbVie Inc
  • 8.2.7 3M Company
  • 8.2.8 Noven Pharmaceuticals Inc
  • 8.2.9 4P Therapeutics LLC
  • 8.2.10 Hisamitsu Pharmaceutical Co. Inc